{"id":"abciximab","rwe":[],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Integrin alpha-IIb/beta-3","category":"target"},{"label":"ITGA2B","category":"gene"},{"label":"ITGB3","category":"gene"},{"label":"B01AC13","category":"atc"},{"label":"Active","category":"status"},{"label":"Percutaneous coronary intervention","category":"indication"},{"label":"Centocor Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":162.151,"date":"","count":71,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=162)"},{"llr":123.268,"date":"","count":23,"signal":"Vascular stent thrombosis","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=123)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Johnson & Johnson","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ABCIXIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:55.140650+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Abciximab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:31:03.314911+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:31:01.328551+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ABCIXIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:31:02.005964+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Integrin alpha-V/beta-3 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:31:03.314878+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201584/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:31:02.803325+00:00"}},"allNames":"reopro","offLabel":[],"synonyms":["abciximab","reopro","7E3"],"timeline":[{"date":"1993-12-16","type":"positive","source":"DrugCentral","milestone":"FDA approval (Centocor Inc)"}],"aiSummary":"Reopro (abciximab) is a medication originally developed by Centocor Inc, currently owned by the same company. It targets the integrin alpha-IIb/beta-3, a protein involved in platelet aggregation. Reopro is used to treat patients undergoing percutaneous coronary intervention, and it was FDA-approved in 1993. The commercial status of Reopro is patented, and it is not yet available as a generic medication. Key safety considerations include bleeding risks and allergic reactions.","brandName":"Reopro","ecosystem":[{"indication":"Percutaneous coronary intervention","otherDrugs":[{"name":"apraclonidine","slug":"apraclonidine","company":"Alcon"},{"name":"argatroban","slug":"argatroban","company":"Pfizer"},{"name":"bivalirudin","slug":"bivalirudin","company":"Medicines Co"},{"name":"cangrelor","slug":"cangrelor","company":"Medicines Co"}],"globalPrevalence":null}],"mechanism":{"target":"Integrin alpha-IIb/beta-3","novelty":"Follow-on","targets":[{"gene":"ITGA2B","source":"DrugCentral","target":"Integrin alpha-IIb/beta-3","protein":"Integrin alpha-IIb"},{"gene":"ITGB3","source":"DrugCentral","target":"Integrin alpha-IIb/beta-3","protein":"Integrin beta-3"}],"modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Reopro is a monoclonal antibody that selectively binds to the integrin alpha-IIb/beta-3, inhibiting its interaction with fibrinogen and von Willebrand factor, thereby preventing platelet aggregation and thrombus formation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Abciximab","title":"Abciximab","extract":"Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor."},"commercial":{"launchDate":"1993","_launchSource":"DrugCentral (FDA 1993-12-16, CENTOCOR INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4950","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ABCIXIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ABCIXIMAB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Abciximab","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:20:42.801945","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:31:04.641111+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clopidogrel","drugSlug":"clopidogrel","fdaApproval":"1997-11-17","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ticlopidine","drugSlug":"ticlopidine","fdaApproval":"1991-10-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetylsalicylic acid","drugSlug":"acetylsalicylic-acid","fdaApproval":"1950-04-12","relationship":"same-class"},{"drugName":"dipyridamole","drugSlug":"dipyridamole","fdaApproval":"1961-12-06","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"epoprostenol","drugSlug":"epoprostenol","fdaApproval":"1995-09-20","patentExpiry":"Mar 15, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"iloprost","drugSlug":"iloprost","fdaApproval":"2004-12-29","patentExpiry":"Jul 18, 2044","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eptifibatide","drugSlug":"eptifibatide","fdaApproval":"1998-05-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tirofiban","drugSlug":"tirofiban","fdaApproval":"1998-05-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"treprostinil","drugSlug":"treprostinil","fdaApproval":"2002-05-21","patentExpiry":"Sep 5, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prasugrel","drugSlug":"prasugrel","fdaApproval":"2009-07-10","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cilostazol","drugSlug":"cilostazol","fdaApproval":"1999-01-15","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ticagrelor","drugSlug":"ticagrelor","fdaApproval":"2011-07-20","patentExpiry":"Oct 17, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cangrelor","drugSlug":"cangrelor","fdaApproval":"2015-06-22","patentExpiry":"Nov 10, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vorapaxar","drugSlug":"vorapaxar","fdaApproval":"2014-05-08","patentExpiry":"Dec 23, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selexipag","drugSlug":"selexipag","fdaApproval":"2015-12-21","patentExpiry":"Oct 31, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"abciximab","indications":{"approved":[{"name":"Percutaneous coronary intervention","source":"DrugCentral","snomedId":415070008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clopidogrel","brandName":"clopidogrel","genericName":"clopidogrel","approvalYear":"1997","relationship":"same-class"},{"drugId":"ticlopidine","brandName":"ticlopidine","genericName":"ticlopidine","approvalYear":"1991","relationship":"same-class"},{"drugId":"acetylsalicylic-acid","brandName":"acetylsalicylic acid","genericName":"acetylsalicylic acid","approvalYear":"1950","relationship":"same-class"},{"drugId":"dipyridamole","brandName":"dipyridamole","genericName":"dipyridamole","approvalYear":"1961","relationship":"same-class"},{"drugId":"epoprostenol","brandName":"epoprostenol","genericName":"epoprostenol","approvalYear":"1995","relationship":"same-class"},{"drugId":"iloprost","brandName":"iloprost","genericName":"iloprost","approvalYear":"2004","relationship":"same-class"},{"drugId":"eptifibatide","brandName":"eptifibatide","genericName":"eptifibatide","approvalYear":"1998","relationship":"same-class"},{"drugId":"tirofiban","brandName":"tirofiban","genericName":"tirofiban","approvalYear":"1998","relationship":"same-class"},{"drugId":"treprostinil","brandName":"treprostinil","genericName":"treprostinil","approvalYear":"2002","relationship":"same-class"},{"drugId":"prasugrel","brandName":"prasugrel","genericName":"prasugrel","approvalYear":"2009","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03744000","phase":"NA","title":"Deferred Stenting in Patients With Anterior Wall STEMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2018-04-03","conditions":["Acute Myocardial Infarction With ST Elevation","Anterior Wall Myocardial Infarction"],"enrollment":185,"completionDate":"2025-11-30"},{"nctId":"NCT01020383","phase":"PHASE2","title":"Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2009-09","conditions":["Unstable Angina","Non ST Segment Elevation Myocardial Infarction (NSTEMI)","Stable Angina (Associated With High Risk PCI)"],"enrollment":364,"completionDate":"2012-03"},{"nctId":"NCT01673893","phase":"","title":"ClearWay Rx Readmission Registry","status":"COMPLETED","sponsor":"Cardiovascular Institute of the South Clinical Research Corporation","startDate":"2011-09","conditions":["Acute Myocardial Infarction"],"enrollment":59,"completionDate":"2014-04"},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":["Stable Angina"],"enrollment":36,"completionDate":"2009-06"},{"nctId":"NCT00046293","phase":"PHASE2","title":"ReoPro and Retavase to Treat Acute Stroke","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-09-24","conditions":["Cerebrovascular Accident"],"enrollment":72,"completionDate":"2007-07-20"},{"nctId":"NCT03087539","phase":"PHASE2","title":"Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients","status":"UNKNOWN","sponsor":"ISU Abxis Co., Ltd.","startDate":"2013-05","conditions":["Acute Myocardial Infarction"],"enrollment":146,"completionDate":"2017-06"},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":["Acute Coronary Syndrome"],"enrollment":2198,"completionDate":"2014-08"},{"nctId":"NCT00178451","phase":"PHASE1,PHASE2","title":"Stroke Prevention With Abciximab in Carotid Endarterectomy","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"","conditions":["Carotid Stenosis"],"enrollment":0,"completionDate":""},{"nctId":"NCT02324348","phase":"NA","title":"Efficacy and Safety Study of Deferred Stenting in Patients With STEMI","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2013-06","conditions":["ST-segment Elevation Myocardial Infarction"],"enrollment":114,"completionDate":"2015-07"},{"nctId":"NCT00269893","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1991-11","conditions":["Angina, Unstable","Angioplasty, Transluminal, Percutaneous Coronary"],"enrollment":2038,"completionDate":"1992-11"},{"nctId":"NCT00271401","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1996-07","conditions":["Angioplasty, Transluminal, Percutaneous Coronary"],"enrollment":2399,"completionDate":"1997-09"},{"nctId":"NCT00269880","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1995-02","conditions":["Angioplasty, Transluminal, Percutaneous Coronary"],"enrollment":2792,"completionDate":"1995-12"},{"nctId":"NCT00269906","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1993-05","conditions":["Angina, Unstable","Angioplasty, Transluminal, Percutaneous Coronary"],"enrollment":1265,"completionDate":"1995-12"},{"nctId":"NCT01932554","phase":"PHASE2","title":"Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2013-11","conditions":["Sickle Cell Disease","Hb-SS Disease With Vasoocclusive Pain","Hemoglobin SS Disease With Vasoocclusive Crisis","Other Sickle Cell Disease With Vaso-Occlusive Pain","Hemoglobin SS Disease With Crisis"],"enrollment":0,"completionDate":"2015-03"},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":["Acute Coronary Syndromes","STEMI","NSTEMI"],"enrollment":7200,"completionDate":"2015-12"},{"nctId":"NCT00234585","phase":"PHASE2","title":"Prospective Randomized Study Comparing Renal Artery Stenting (RESIST)With/Without Distal Protection","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2002-08","conditions":["Renal Artery Stenosis"],"enrollment":100,"completionDate":"2007-06"},{"nctId":"NCT00046228","phase":"PHASE3","title":"A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2002-08","conditions":["Myocardial Infarction"],"enrollment":2461,"completionDate":"2008-01"},{"nctId":"NCT02181985","phase":"PHASE3","title":"Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-05","conditions":["Myocardial Infarction"],"enrollment":5989,"completionDate":""},{"nctId":"NCT02016547","phase":"PHASE4","title":"Thrombectomy Under Reopro Versus Alteplase to Treat Stoke","status":"TERMINATED","sponsor":"SOS Attaque Cérébrale","startDate":"2013-09","conditions":["Infarction, Middle Cerebral Artery"],"enrollment":40,"completionDate":"2015-02"},{"nctId":"NCT02105870","phase":"NA","title":"A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function","status":"UNKNOWN","sponsor":"University of Melbourne","startDate":"2012-02","conditions":["Myocardial Infarction","Coronary Artery Disease"],"enrollment":40,"completionDate":"2014-06"},{"nctId":"NCT00379418","phase":"","title":"Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-01","conditions":["Coronary Artery Disease"],"enrollment":220,"completionDate":"2009-12"},{"nctId":"NCT00976521","phase":"NA","title":"The INFUSE - Anterior Myocardial Infarction (AMI) Study","status":"COMPLETED","sponsor":"Atrium Medical Corporation","startDate":"2009-09","conditions":["Acute Anterior Myocardial Infarction"],"enrollment":452,"completionDate":"2013-04"},{"nctId":"NCT00440895","phase":"PHASE4","title":"A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI","status":"COMPLETED","sponsor":"Olivier F. Bertrand","startDate":"2007-02","conditions":["Myocardial Infarction","Ischemia"],"enrollment":74,"completionDate":"2013-05"},{"nctId":"NCT01404507","phase":"PHASE4","title":"Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-12","conditions":["Acute Myocardial Infarction"],"enrollment":40,"completionDate":"2012-02"},{"nctId":"NCT00894023","phase":"PHASE3","title":"Intracoronary Abciximab With Clearway Catheter","status":"TERMINATED","sponsor":"Gennaro Sardella","startDate":"2009-06","conditions":["Acute Myocardial Infarction"],"enrollment":150,"completionDate":"2011-06"},{"nctId":"NCT01757457","phase":"PHASE4","title":"Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2006-04","conditions":["Myocardial Infarction"],"enrollment":89,"completionDate":"2008-04"},{"nctId":"NCT01475552","phase":"PHASE4","title":"Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-09","conditions":["Diabetes Mellitus"],"enrollment":130,"completionDate":"2011-10"},{"nctId":"NCT00426751","phase":"PHASE3","title":"Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":["Infarction, Myocardial"],"enrollment":429,"completionDate":"2007-12"},{"nctId":"NCT00373451","phase":"PHASE4","title":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":["Myocardial Infarction","Coronary Disease"],"enrollment":1721,"completionDate":"2011-07"},{"nctId":"NCT00590070","phase":"PHASE2,PHASE3","title":"THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2008-01","conditions":["Myocardial Infarction"],"enrollment":240,"completionDate":"2011-09"},{"nctId":"NCT01383785","phase":"PHASE4","title":"Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab","status":"UNKNOWN","sponsor":"Hospital Virgen de la Salud","startDate":"2009-11","conditions":["Myocardial Infarction","Occlusive Thrombus"],"enrollment":186,"completionDate":"2012-12"},{"nctId":"NCT01499407","phase":"PHASE4","title":"Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction","status":"UNKNOWN","sponsor":"CLI Foundation","startDate":"2011-12","conditions":["ST-elevation Myocardial Infarction"],"enrollment":128,"completionDate":"2013-04"},{"nctId":"NCT00440778","phase":"PHASE4","title":"A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI","status":"COMPLETED","sponsor":"Laval University","startDate":"2007-02","conditions":["Myocardial Infarction","Ischemia"],"enrollment":105,"completionDate":"2008-10"},{"nctId":"NCT00354406","phase":"PHASE4","title":"Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2006-04","conditions":["Myocardial Infarction"],"enrollment":110,"completionDate":"2008-12"},{"nctId":"NCT00229515","phase":"PHASE4","title":"Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI","status":"UNKNOWN","sponsor":"Marco Valgimigli","startDate":"2004-11","conditions":["Myocardial Infarction"],"enrollment":744,"completionDate":"2012-03"},{"nctId":"NCT00039832","phase":"PHASE2","title":"ReoPro and Retavase to Restore Brain Blood Flow After Stroke","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-03","conditions":["Cerebrovascular Accident"],"enrollment":42,"completionDate":"2008-05"},{"nctId":"NCT00685464","phase":"NA","title":"Intravenous Versus Intracoronary Use of Abciximab","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2006-01","conditions":["Atherosclerosis","Ischemic Heart Disease"],"enrollment":355,"completionDate":"2009-12"},{"nctId":"NCT00986050","phase":"PHASE4","title":"Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2006-01","conditions":["Acute Myocardial Infarction"],"enrollment":907,"completionDate":"2009-07"},{"nctId":"NCT00073372","phase":"PHASE3","title":"A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)","status":"TERMINATED","sponsor":"Centocor, Inc.","startDate":"2003-10","conditions":["Cerebrovascular Accident","Brain Ischemia","Acute Disease"],"enrollment":808,"completionDate":"2005-12"},{"nctId":"NCT00712101","phase":"PHASE3","title":"Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2008-07","conditions":["ST-elevation Myocardial Infarction"],"enrollment":1912,"completionDate":"2011-04"},{"nctId":"NCT00927615","phase":"NA","title":"Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2008-09","conditions":["ST-Elevation Myocardial Infarction"],"enrollment":534,"completionDate":"2011-04"},{"nctId":"NCT01158846","phase":"PHASE4","title":"Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI","status":"UNKNOWN","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2010-08","conditions":["ST-Elevation Myocardial Infarction","Primary Percutaneous Coronary Intervention"],"enrollment":800,"completionDate":"2011-06"},{"nctId":"NCT00841438","phase":"PHASE4","title":"Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2007-07","conditions":["Myocardial Infarction"],"enrollment":786,"completionDate":"2009-12"},{"nctId":"NCT00133250","phase":"PHASE4","title":"Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-06","conditions":["Myocardial Infarction"],"enrollment":800,"completionDate":"2008-03"},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":["Coronary Disease","Angina Pectoris"],"enrollment":4570,"completionDate":"2008-05"},{"nctId":"NCT01080638","phase":"PHASE4","title":"Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2009-10","conditions":["Myocardial Infarction","Angioplasty"],"enrollment":150,"completionDate":"2010-12"},{"nctId":"NCT00638638","phase":"PHASE3","title":"Myocardial Infarction With ST-Elevation","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2005-01","conditions":["Myocardial Infarction"],"enrollment":292,"completionDate":"2010-01"},{"nctId":"NCT00929279","phase":"PHASE4","title":"Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2008-11","conditions":["Acute Coronary Syndrome"],"enrollment":73,"completionDate":"2009-05"},{"nctId":"NCT00420030","phase":"PHASE4","title":"Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2006-09","conditions":["Shock, Cardiogenic"],"enrollment":80,"completionDate":"2009-06"},{"nctId":"NCT00442949","phase":"NA","title":"Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndrome (ACS)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-08","conditions":["Acute Coronary Syndrome"],"enrollment":400,"completionDate":"2009-01"},{"nctId":"NCT00507338","phase":"PHASE2","title":"Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI","status":"TERMINATED","sponsor":"Archemix Corp.","startDate":"2007-10","conditions":["Acute Myocardial Infarction"],"enrollment":300,"completionDate":"2008-02"},{"nctId":"NCT00806403","phase":"PHASE4","title":"Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2001-11","conditions":["Acute Myocardial Infarction"],"enrollment":205,"completionDate":"2004-06"},{"nctId":"NCT00759629","phase":"PHASE4","title":"Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2001-05","conditions":["Myocardial Infarction"],"enrollment":365,"completionDate":"2005-08"},{"nctId":"NCT00299377","phase":"PHASE2,PHASE3","title":"Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2006-01","conditions":["Myocardial Infarction"],"enrollment":150,"completionDate":"2008-02"},{"nctId":"NCT00260416","phase":"PHASE2","title":"Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours","status":"COMPLETED","sponsor":"Aarhus University Hospital Skejby","startDate":"2005-05","conditions":["Acute Myocardial Infarction"],"enrollment":60,"completionDate":"2007-12"},{"nctId":"NCT00133003","phase":"PHASE4","title":"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-03","conditions":["Coronary Disease","Angina, Unstable"],"enrollment":2022,"completionDate":"2006-01"},{"nctId":"NCT00383136","phase":"PHASE4","title":"FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab","status":"COMPLETED","sponsor":"University of Bologna","startDate":"2003-06","conditions":["Acute Myocardial Infarction"],"enrollment":692,"completionDate":"2007-09"},{"nctId":"NCT00220571","phase":"PHASE3","title":"CARESS in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Società Italiana di Cardiologia Invasiva","startDate":"2003-05","conditions":["Myocardial Infarction"],"enrollment":600,"completionDate":"2007-03"},{"nctId":"NCT00378391","phase":"","title":"European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2005-11","conditions":["ST-Elevation Myocardial Infarction","Acute Coronary Syndrome"],"enrollment":1800,"completionDate":"2007-02"},{"nctId":"NCT00126139","phase":"PHASE3","title":"Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2004-04","conditions":["Stroke","Stenosis"],"enrollment":100,"completionDate":"2005-05"},{"nctId":"NCT00167765","phase":"PHASE3","title":"Abciximab in Wake-up Stroke","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2005-03","conditions":["Stroke"],"enrollment":50,"completionDate":"2005-05"},{"nctId":"NCT00169819","phase":"PHASE4","title":"EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study","status":"COMPLETED","sponsor":"Laval University","startDate":"2003-10","conditions":["Coronary Artery Disease","Ischemia"],"enrollment":1000,"completionDate":"2006-04"},{"nctId":"NCT00163254","phase":"PHASE2","title":"Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2003-09","conditions":["Patients Above 18 Years"],"enrollment":0,"completionDate":"2006-11"},{"nctId":"NCT00156611","phase":"PHASE2,PHASE3","title":"Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2002-01","conditions":["Arterial Occlusive Diseases"],"enrollment":420,"completionDate":"2009-12"},{"nctId":"NCT00320229","phase":"PHASE4","title":"Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen","status":"TERMINATED","sponsor":"Azienda Sanitaria Ospedaliera","startDate":"2004-12","conditions":["Coronary Disease","Myocardial Infarction"],"enrollment":84,"completionDate":"2005-07"},{"nctId":"NCT00288210","phase":"PHASE4","title":"Sirolimus Eluting Stenting in Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"San Camillo Hospital, Rome","startDate":"2003-03","conditions":["Myocardial Infarction"],"enrollment":0,"completionDate":"2006-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000148393","MMSL":"1007","NDDF":"004907","UNII":"X85G7936GV","VUID":"4020901","VANDF":"4020901","INN_ID":"7200","RXNORM":"152293","UMLSCUI":"C0288672","chemblId":"CHEMBL1201584","ChEMBL_ID":"CHEMBL1201584","KEGG_DRUG":"D02778","DRUGBANK_ID":"DB00054","SNOMEDCT_US":"108974006","IUPHAR_LIGAND_ID":"6584","MESH_DESCRIPTOR_UI":"D000077284"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1993-","companyName":"Centocor Inc","relationship":"Original Developer"}],"publicationCount":2113,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AC13","allCodes":["B01AC13"]},"biosimilarFilings":[],"originalDeveloper":"Centocor Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Johnson & Johnson","companyId":"johnson-johnson","modality":"Monoclonal antibody","firstApprovalDate":"1993","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:31:04.641111+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}